Senate Democrats ended up not tweaking a provision that delays Medicare price negotiation for select high-cost drugs with biosimilar alternatives about to enter the market for up to two years in the final text of their reconciliation bill, which passed the Senate over the weekend. Biosimilars lobbyists had hoped Democrats would simplify the provision by simply delaying negotiation for two years, which they said would strengthen the policy and limit CMS discretion. Biosimilars advocates say the Senate reconciliation bill language,...